HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…</p><p dir="ltr">Compared to the ECIB algorithm and previous approaches, HDECO achieved significant improvements:</p><ul><li><b>Up to 10% reduction in energy consumption</b></li><li><b>8% decrease in overall execution cost</b></li><li><b>Better real execution time and fewer unnecessary migrations</b></li></ul><p dir="ltr">This makes HDECO an effective and lightweight solution for instance-intensive cloud workflows.…”

Adjusted surgical quality, adjusted cost, and market shares of innovative procedures, 2002–2015. by Ning Ning (464160)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

ITSA regression results of weekly total cost and cost components per capita for inpatients in the non-surgical group before and after DIP payment intervention. by Chenxuan Zhu (22622476)

Subjects:

Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

Subjects:

SCD results of the cost structure for inpatients in the non-surgical group. by Chenxuan Zhu (22622476)

Subjects:

Unadjusted and adjusted annualized growth rates of quality and cost for 11 surgery categories, 2002–2015. by Ning Ning (464160)

Subjects:

Unadjusted rates of high-quality stays and cost for 11 inpatient surgery categories, 2002–2015. by Ning Ning (464160)

Subjects:

Time cost of natural environment. by Jilei Tao (20208621)

“…The results show a significant improvement in accessibility of tourist attractions from 2015 to 2024, with average travel time to tourist attractions at the county level decreasing from 65 to 41 minutes, and the proportion of areas reachable within 60 minutes rising from 62.5% to 92.3%. …”

Giving credit to reforestation for water quality benefits - Fig 5 by Arturo A. Keller (119450)

Costs savings breakdown per tray. by Jay Toor (14309485)

Subjects:

Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs by Chris Wallick (10131528)

One-way sensitivity analysis. by Yiping An (20609789)

Subjects:

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Cost-effectiveness acceptability curve. by Yiping An (20609789)

Subjects:

Mini-Medical School Programs Decrease Perceived Barriers of Pursuing Medical Careers Among Underrepresented Minority High School Students by Abraham Abdulrazzak (9570086)

“…This study highlights the benefit of mini-medical school programs, especially programs with a mentoring component, to decrease perceived barriers of applying to medical school among URMs and suggests the potential role of similar programs to increase diversity in medicine and to decrease healthcare disparities among minorities in the United States.…”

Both cis- and trans-cycles decrease in number upon treatment with auxin. by Manu Aggarwal (15990691)

Summary of risks, benefits, and examples of commercial products for major microbial genes. by Saiko Sugita (14581134)